Company / Shareholders' Equity
10x Genomics, Inc. Shareholders' Equity History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$796.3M
FY2025
5-year range
$420.1M / $796.3M
FY2021-FY2025
Trend
+12.1%
vs FY2024
Sector context
#91 of 161
Health Care
What the data says
At $796M, 10x Genomics, Inc.'s shareholders' equity ranks #91 of 161 in the Health Care sector. Shareholders' Equity has fluctuated over the past 9 years, ranging from -$220M in FY2018 to $796M in FY2025.
Based on SEC 10-K filings.
$796M in FY2025 with a 5-year CAGR of +1.5%.
Improved from $741M to $796M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- +2.5%
- 5-Year CAGR
- +1.5%
- 10-Year CAGR
- -
Sector benchmark
#91 of 161 in Health CareTop 57% of 161This company $796.3M Sector average $5.1B
▼
-84.3% below sector average
Key checks
Key Insights
- 5-year CAGR of +1.5%, indicating consistent growth.
- In FY2025, shareholders' equity increased 12.1% year-over-year.
- Ranks #91 out of 161 companies in the Health Care sector.
- Lowest shareholders' equity in the period was in FY2018.
Company context
Key Data Points
- Altman Z-Score 0.94 (distress zone, below 1.8 threshold)
- Negative profit margin: -29.9%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $796.3M | +12.1% |
| FY2024 | $710.1M | -4.2% |
| FY2023 | $741.0M | +0.3% |
| FY2022 | $739.1M | +75.9% |
| FY2021 | $420.1M | -43.2% |
| FY2020 | $739.1M | +75.9% |
| FY2019 | $420.1M | +291.0% |
| FY2018 | -$220.0M | -95.5% |
| FY2017 | -$112.5M | - |
As of FY2025 · SEC 10-K · Updated Jul 1, 2026